These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35397092)

  • 1. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials.
    Eder L; Tony HP; Odhav S; Agirregoikoa EG; Korkosz M; Schwartzman S; Sprabery AT; Gellett AM; Park SY; Bertram CC; Ogdie A
    Rheumatol Ther; 2022 Jun; 9(3):919-933. PubMed ID: 35397092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
    Kameda H; Hagimori K; Morisaki Y; Holzkämper T; Konomi A; Dobashi H
    Rheumatol Ther; 2023 Dec; 10(6):1683-1703. PubMed ID: 37858007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
    Armstrong AW; Jaleel T; Merola JF; Gottlieb AB; Khattri S; Helt CC; Malatestinic WN; Ross SE; Ngantcha ME; de Vlam K
    Dermatol Ther (Heidelb); 2024 Jun; 14(6):1615-1631. PubMed ID: 38814433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.
    Coates LC; Smolen JS; Mease PJ; Husni ME; Merola JF; Lespessailles E; Kishimoto M; Macpherson L; Bradley AJ; Bolce R; Helliwell PS
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36171019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
    Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
    Orbai AM; Gratacós J; Turkiewicz A; Hall S; Dokoupilova E; Combe B; Nash P; Gallo G; Bertram CC; Gellett AM; Sprabery AT; Birt J; Macpherson L; Geneus VJ; Constantin A
    Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.
    Werner SG; Baraliakos X; Reckert S; Bohl-Bühler M; Laliberté MC; Girard T; Jeromin K; Baschuk N; Fritz B; Bessette L; Hueber AJ
    Rheumatol Ther; 2023 Dec; 10(6):1503-1518. PubMed ID: 37695506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
    Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
    Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filling the "GAP" in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint.
    Tillett W; Birt J; Vadhariya A; Ross S; Ngantcha M; Ng KJ
    Rheumatol Ther; 2024 Oct; 11(5):1101-1114. PubMed ID: 38955921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors.
    Nash P; Behrens F; Orbai AM; Rathmann SS; Adams DH; Benichou O; Deodhar A
    RMD Open; 2018; 4(2):e000692. PubMed ID: 30233812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.
    Kavanaugh A; Mease P; Gossec L; Ranza R; Tsuji S; Douglas K; Lane M; Lippe R; Mittal M; Gao T; Setty A; Ciecinski S; Aletaha D; Nash P
    ACR Open Rheumatol; 2024 Aug; ():. PubMed ID: 39087872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
    Coates LC; Ritchlin CT; Gossec L; Helliwell PS; Rahman P; Kollmeier AP; Xu XL; Shawi M; Karyekar CS; Contré C; Noël W; Sheng S; Wang Y; Xu S; Mease PJ
    Rheumatology (Oxford); 2023 Feb; 62(2):606-616. PubMed ID: 35766811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study.
    Leung YY; Eder L; Orbai AM; Coates LC; de Wit M; Smolen JS; Kiltz U; Palominos P; Canete JD; Scrivo R; Balanescu A; Dernis E; Meisalu S; Soubrier M; Kalyoncu U; Gossec L
    RMD Open; 2023 Sep; 9(3):. PubMed ID: 37709527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.